Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice

Area of Science:

• Muscle Diseases
• Genetics
• Biochemistry

Background:

• Centronuclear myopathies (CNM) are debilitating non-dystrophic muscle diseases with no current effective treatments.
• X-linked CNM stems from myotubularin 1 (MTM1) loss-of-function, while autosomal dominant forms involve dynamin2 (DNM2) mutations.
• Previous research indicated that reducing DNM2 expression mitigates muscle pathology in Mtm1 knockout (Mtm1KO) mice.

Purpose of the Study:

• To evaluate the therapeutic potential of antisense oligonucleotides (ASOs) for systemic delivery in treating MTM1-deficient centronuclear myopathy.
• To assess the efficacy of DNM2 knockdown via ASOs in preventing and reversing muscle pathology in Mtm1KO mice.

Main Methods:

• Systemic administration of Dnm2 antisense oligonucleotides (ASOs) to Mtm1 knockout mice.
• Quantification of DNM2 protein levels in muscle tissue.
• Histological analysis to evaluate muscle pathology reversal.

Main Results:

• Systemic ASO delivery effectively reduced DNM2 protein levels in the muscles of Mtm1KO mice.
• ASO treatment prevented the development of muscle pathology in Mtm1KO mice.
• In severely affected mice, ASO injections led to a significant reversal of muscle pathology within two weeks.

Conclusions:

• ASO-mediated knockdown of DNM2 is a viable therapeutic strategy for MTM1-deficient centronuclear myopathy.
• This approach demonstrates the potential to correct muscle defects and reverse pathology, offering hope for a new CNM therapy.